272
Participants
Start Date
June 30, 2003
Primary Completion Date
December 31, 2011
Study Completion Date
May 31, 2012
Peginterferon alfa-2a plus ribavirin for HCV genotype 1
Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight \<75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3
Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
Asan Medical Center, Seoul
Lead Sponsor
Samsung Medical Center
OTHER
Severance Hospital
OTHER
Gangnam Severance Hospital
OTHER
Seoul St. Mary's Hospital
OTHER
Korea University Guro Hospital
OTHER
Asan Medical Center
OTHER